

# mariposa HEALTH

(ABN 67 134 154 680)

## Shareholder Newsletter October 2014

Dear Shareholder,

Either today or tomorrow you will have received a Notice of Meeting for our AGM to take place on 30 October. The Notice includes several items of housekeeping that we bring to your attention.

### **Path to US listing**

In our Shareholders' letter of August, we commented that we were investigating the path to listing on a US stock exchange. We can now add to this by advising that, having completed the Audit of our accounts for Australian purposes, we have engaged advisors to take us through the process for US listing. We have retained a US Investment Bank, as advisor and underwriter to a Nasdaq listing. In addition we have retained, US based or focused legal, accounting and audit advisors as well as an Australian-based corporate advisors to the transaction.

The intended process is for shares in Mariposa Health to be converted to shares in a company listed on an OTC board in the US, in process similar to a reverse takeover onto the ASX, with a secondary move to a major Board occurring a few months after the initial acquisition. Full details will be described as matters progress.

### **Out-license for Chinese market**

During August we provided our Chinese partners with a detailed Term sheet for the licensing of one product for COPD for the territories of China and related areas. As previously commented, this was after an exhaustive due diligence of all technical matters. We have now been invited to meet with our counterparts to discuss commercial terms and the collaborative process. We are very pleased with the progress and expect to visit their premises later this month.


### **Next steps?**

We hope to have more information on each of the above to be available by the AGM at the end of October. In the mean-time, we work towards completing to matters described above and then to re-orient ourselves to operational matters.

We are seeking working capital to allow completion of the above matters and invite shareholders to participate to take the opportunity of what should be the final opportunity to invest at seed valuations.

Thank you for your patience and continued support. As always, please feel free to call me to discuss any of the above matters.

Yours faithfully,



Phillip Comans  
Executive Chairman